ArticleBMC infectious diseases2026
The first outbreak of neuroinvasive West Nile virus infection in Istanbul area within 2019.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTurkiye has reported West Nile virus (WNV) infection outbreaks since 2010. The first—and until then only—local human case in Istanbul was recorded in 2017, followed by an outbreak in 2019.
aimsWe describe this first known documented outbreak of neuroinvasive WNV (NWNV) infection in the Istanbul region during the summer and autumn of 2019. STUDY
designRetrospective, multi-center, cohort study.
methodsBetween July and September 2019, 16 cases of NWNV infection were hospitalized at six referral hospitals in Istanbul. Additionally, we included one resident case diagnosed and treated at Istanbul School of Medicine Hospital in 2017, representing the first known confirmed—but previously unreported—WNV infection in Istanbul.
resultsAmong total 17 cases, 14 had meningoencephalitis, two meningitis, and one flaccid paralysis. Median age was 63 years; 65% were male. Most lived in the European part of Istanbul near lakes or dams, but only 24% (4/17) reported recent mosquito exposure. Median symptom duration before admission was 6 (0–24) days. Underlying conditions were present in 82% (14/17), most commonly hypertension (41%), diabetes (35%), chronic kidney disease (CKD) (18%), and onco-hematological diseases (18%). WNV serology (IgM, IgG), plaque reduction neutralization test, PCR, and IgG avidity testing were performed except CSF IgM. There was one in-hospital mortality case with CKD after 76 days of hospitalization. Neurological sequelae occurred in 47% (8/17), including lower limb paresis (n = 3), parkinsonian gait, aphasia, sensorineural hearing loss, respiratory muscle weakness, and retinitis (one each).
conclusionNWNV infection should be considered as a potential cause of meningoencephalitis in Istanbul, particularly during the summer and autumn months. Patients presenting with gastrointestinal or flu-like symptoms followed by ataxia, dysarthria, slowed speech, tremor, or ocular abnormalities should be tested for WNV infection. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.